Leap Therapeutics Inc - Strategy, SWOT and Corporate Finance Report

Leap Therapeutics Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company

Key Highlights

Leap Therapeutics Inc (Leap Therapeutics) is a clinical-stage biopharmaceutical company that develops novel therapeutics to treat patients with cancer. The company’s pipeline products include DKN-01and TRX518. DKN-0 is a humanized monoclonal antibody that targets the Dickkopf-1 (DKK-1) protein, intended for the treatment of gastroesophageal cancer, hepatocellular carcinoma, prostate cancer and gynecologic cancers. TRX518 is a humanized anti-GITR (glucocorticoid-induced tumor necrosis factor receptor) monoclonal antibody that enhances the immune system’s anti-tumor response and is in Phase 1 clinical trials intended for the treatment of solid tumors. Leap Therapeutics is headquartered in Cambridge, Massachusetts, the US.

Scope

  • Detailed information on Leap Therapeutics Inc required for business and competitor intelligence needs
  • A study of the major internal and external factors affecting Leap Therapeutics Inc in the form of a SWOT analysis
  • An in-depth view of the business model of Leap Therapeutics Inc including a breakdown and examination of key business segments
  • News about Leap Therapeutics Inc, such as business expansion, restructuring, and contract wins
  • Large number of easy-to-grasp charts and graphs that present important data and key trends

Reasons to buy

  • Gain understanding of Leap Therapeutics Inc and the factors that influence its strategies.
  • Track strategic initiatives of the company and latest corporate news and actions.
  • Assess Leap Therapeutics Inc as a prospective partner, vendor or supplier.
  • Support sales activities by understanding your customers' businesses better.
  • Stay up to date on Leap Therapeutics Incs business structure, strategy and prospects.

Note: Some sections may be missing if data is unavailable for the company.

Companies mentioned

TG Therapeutics Inc

Novartis Corp

Incyte Corporation Ltd

Bristol-Myers Squibb Co

Astrazeneca Pty Ltd

TG Therapeutics Inc

Novartis Corp

Incyte Corporation Ltd

Bristol-Myers Squibb Co

Astrazeneca Pty Ltd

Table of Contents

Table of Contents

Table of Contents

List of Tables

List of Figures

Section 1 - About the Company

Leap Therapeutics Inc - Key Facts

Leap ...

Table of Contents

Table of Contents

List of Tables

List of Figures

Section 1 - About the Company

Leap Therapeutics Inc - Key Facts

Leap Therapeutics Inc - Key Employees

Leap Therapeutics Inc - Key Employee Biographies

Leap Therapeutics Inc - Major Products and Services

Leap Therapeutics Inc - History

Leap Therapeutics Inc - Company Statement

Leap Therapeutics Inc - Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Section 2 – Company Analysis

Company Overview

Leap Therapeutics Inc - Business Description

Leap Therapeutics Inc - SWOT Analysis

SWOT Analysis - Overview

Leap Therapeutics Inc - Strengths

Leap Therapeutics Inc - Weaknesses

Leap Therapeutics Inc - Opportunities

Leap Therapeutics Inc - Threats

Leap Therapeutics Inc - Key Competitors

Section 3 – Company Financial Ratios

Financial Ratios - Capital Market Ratios

Financial Ratios - Annual Ratios

Performance Chart

Financial Performance

Financial Ratios - Interim Ratios

Financial Ratios - Ratio Charts

Section 4 – Company’s Lifesciences Financial Deals and Alliances

Leap Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

Leap Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019

Leap Therapeutics Inc, Recent Deals Summary

Section 5 – Company’s Recent Developments

Apr 01, 2019: Leap Therapeutics reports clinical update and 2018 financial results

Aug 08, 2018: Leap Therapeutics reports second quarter 2018 business update and financial results

Jul 25, 2018: Leap, Merck and Pfizer partner to start Phase I/II trial for tumours

May 11, 2018: Leap Therapeutics Reports First Quarter 2018 Financial Results

Feb 23, 2018: Leap Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results

Section 6 – Appendix

Methodology

Ratio Definitions

About GlobalData

Contact Us

Disclaimer

List of Tables

List of Tables

Leap Therapeutics Inc, Key Facts

Leap Therapeutics Inc, Key Employees

Leap Therapeutics Inc, Key Employee Biographies

Leap Therapeutics Inc, Major Products and ...

List of Tables

Leap Therapeutics Inc, Key Facts

Leap Therapeutics Inc, Key Employees

Leap Therapeutics Inc, Key Employee Biographies

Leap Therapeutics Inc, Major Products and Services

Leap Therapeutics Inc, History

Leap Therapeutics Inc, Subsidiaries

Leap Therapeutics Inc, Key Competitors

Leap Therapeutics Inc, Ratios based on current share price

Leap Therapeutics Inc, Annual Ratios

Leap Therapeutics Inc, Annual Ratios (Cont...1)

Leap Therapeutics Inc, Interim Ratios

Leap Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

Leap Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019

Leap Therapeutics Inc, Recent Deals Summary

Currency Codes

Capital Market Ratios

Equity Ratios

Profitability Ratios

Cost Ratios

Liquidity Ratios

Leverage Ratios

Efficiency Ratios

List of Figures

List of Figures

Leap Therapeutics Inc, Performance Chart (2014 - 2018)

Leap Therapeutics Inc, Ratio Charts

Leap Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, ...

List of Figures

Leap Therapeutics Inc, Performance Chart (2014 - 2018)

Leap Therapeutics Inc, Ratio Charts

Leap Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

Leap Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019

    Pricing

Discounts available for multiple report purchases.

reportstore@marketline.com
+44 (0) 161 359 5817

Saved reports